News

2010

May 18, 2010
Pearl Therapeutics’ Data for its Combination Bronchodilator Product, PT003, Support the Potential for Improvement in the Treatment of Patients with COPD

May 17, 2010
Pearl Therapeutics Receives TiE50 Entrepreneur Award

May 5, 2010
Pearl Therapeutics’ Bronchodilator Combination Therapeutic for COPD to Be Presented at the American Thoracic Society Annual Meeting

March 29, 2010
Pearl Therapeutics Announces Positive Results from Phase 1 Trial of PT003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial

February 1, 2010
Pearl Therapeutics Raises $15 Million to Advance PT003, LAMA/LABA Combination Bronchodilator for COPD, into Phase 2b Study

January 6, 2010
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease

January 4, 2010
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease

2009

November 23, 2009
Pearl Therapeutics Appoints Howie Rosen to Board of Directors

March 02, 2009
Pearl Therapeutics Appoints Perry Karsen as CEO

February 24, 2009
Pearl Therapeutics Secures $8 Million in Debt Financing

2008

July 02, 2008
Pearl Therapeutics Closes $18 Million Financing

2007

December 20, 2007
Pearl Therapeutics, Inc. Expands Its Senior Management Team with Top Talent in Clinical Development and Regulatory Affairs

September 04, 2007
Pearl Therapeutics Raises $15.5 Million in Private Financing